Telix Pharmaceuticals rises on first US patient dosing for brain cancer drug

Telix Pharmaceuticals shares rose as much as 5.5% to A$16.26, their largest intraday percentage gain since Sept. 22, after the company announced that the first patients in the U.S. had been dosed with its FDA-approved glioma imaging drug, Pixclara.